US Edition
OpenAI Has a New AI Model Built for Biology and Science
The biology-tuned model is designed to synthesize evidence, generate hypotheses and plan experiments, with a research preview limited to qualified U.S. enterprises.
- On Thursday, San Francisco-based OpenAI launched the GPT-Rosalind model, a specialized system designed to accelerate drug discovery and biological research by synthesizing complex scientific workflows.
- Traditional life sciences research is 'fragmented and difficult to scale,' often spanning 10 to 15 years as scientists manually pivot between experimental equipment, software, and disparate databases.
- In granular testing via LABBench2, the model outperformed GPT-5.4 on six out of eleven tasks, while connecting to over 50 public multi-omics databases to automate scientific lookups.
- OpenAI is limiting access to qualified United States-based organizations through a 'Trusted Access' program, citing safety concerns regarding potential harmful outputs like optimizing virus infectivity.
- By collaborating with Amgen, Moderna, and Los Alamos National Laboratory, the company positions GPT-Rosalind as a 'capable partner in discovery' to compress years of R&D into actionable insights.
33 Articles
33 Articles
The GPT-Rosalind model is designed to accelerate research in biology and drug development. OpenAI has introduced a new artificial intelligence model, which aims to support scientific research in biology, drug discovery and translational medicine (the field of medicine that connects scientific research with clinical practice). This new tool, called GPT-Rosalind, is named after Rosalind Franklin, the British scientist known for her important contr…
OpenAI launches GPT-Rosalind, an AI model for life sciences research
Named after the crystallographer who helped reveal the structure of DNA, GPT-Rosalind is OpenAI’s first domain-specific model series, fine-tuned for biochemistry, genomics, and protein engineering. Access is restricted to a trusted-access programme for vetted enterprise customers including Amgen, Moderna, and Thermo Fisher Scientific. OpenAI has launched GPT-Rosalind, a frontier reasoning model built specifically for life […] This story continue…
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
